Targeted iron oxide nanogels for ovarian cancer hyperthermia therapy

靶向氧化铁纳米凝胶用于卵巢癌热疗

• 批准号: 2825192
• 金额: --
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2825192
• 关键词: Targeted; iron; oxide; nanogels; ovarian

Ovarian cancer is the main gynaecological killer of women in the UK with around 7,500 women being diagnosed with ovarian cancer each year. Better treatments are necessary in order to combat the disease and help patients live longer. This project aims to develop a highly novel targeted magnetic nanotherapy that can kill cancer cells in two ways, both through heat and also the release of an anticancer drug. Magnetic nanocarriers are a highly versatile platform for cancer therapy as they can deliver heat and drugs local to the cancer cells. In this project magnetic nano-composites (MNCs) made of an iron oxide nanostructure core will be developed in the Thanh lab and characterised. Subsequently the iron oxide nanoflowers (cluster of nanoparticles) will then act as templates around which a nanogel shell will be polymerised in the Kamaly lab that will include the following components: a heat responsive element that will lead to the release of olaparib and a targeting ligand that will specifically target ovarian cancer cells. The nanoparticles will be extensively tested for their hyperthermic and magnetic properties in the Thanh lab and subsequently characterised for their size, shape, surface charge, degradation in response to heat and ovarian cancer cell targeting abilities in the Kamaly lab. Furthermore, the synergistic and combinatorial effects of hyperthermia + olaparib therapy will be tested on advanced ovarian cancer cells in vitro. It is hoped that this novel therapy will bridge the gap in multimodal ovarian cancer therapy whereby combinations of imaging and therapeutic agents can be investigated. The project is proposed to adhere to the following timeline: PhD yr 1: Synthesis of core MNCs (NT lab) and surface functionalization (NK lab). Nanoparticle characteristion (TEM and DLS)PhD yr 2: Further characterization of MNCs (Japan, XPS, HRTEM, STEM) PhD yr 3: In vitro and in vivo investigations of MNCs in Ovarian cancer models.

卵巢癌是英国女性的主要妇科杀手，每年约有7500名女性被诊断出患有卵巢癌。为了抗击这种疾病，帮助患者活得更长，有必要进行更好的治疗。该项目旨在开发一种高度新颖的靶向磁性纳米疗法，可以通过两种方式杀死癌细胞，一种是通过加热，另一种是通过释放抗癌药物。磁性纳米载体是癌症治疗的一个高度通用的平台，因为它们可以将热量和药物局部传递给癌细胞。在这个项目中，将在Thanh实验室开发由氧化铁纳米结构核心制成的磁性纳米复合材料(MNC)，并对其进行表征。随后，氧化铁纳米花(纳米粒子簇)将作为模板，在Kamaly实验室中围绕其聚合纳米凝胶壳，该壳将包括以下成分：将导致奥拉帕利释放的热响应元件和将专门针对卵巢癌细胞的靶向配体。这些纳米粒子将在Thanh实验室进行广泛的耐热和磁性测试，随后在Kamaly实验室对其尺寸、形状、表面电荷、对热的降解以及卵巢癌细胞靶向能力进行表征。此外，将在体外测试热疗+奥拉帕利治疗晚期卵巢癌细胞的协同作用和联合作用。人们希望这种新的治疗方法将填补多模式卵巢癌治疗的空白，从而可以研究成像和治疗药物的组合。该项目拟遵循以下时间表：博士年头1：核心多核细胞的合成(NT LAB)和表面功能化(NK LAB)。纳米颗粒特性(TEM和DLS)PHD YR 2：MNC的进一步特性(日本，XPS，HRTEM，STEM)PHD YR 3：卵巢癌模型中MNC的体外和体内研究。